Study on the Therapeutic Effect of TCM Treatment for MDR MN

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effectiveness and safety of the Chinese medicine treatment for multiple drug resistance of MN patients with Jianpiyiqi and Huoxuejiedu Recipe.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai University of Traditional Chinese Medicine
• Collaborators: Changhai Hospital; Chinese Academy of Sciences; Fudan University; Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Guangxi Traditional Chinese Medical University; Huashan Hospital; Nanjing University of Traditional Chinese Medicine; RenJi Hospital; Ruijin Hospital; Shanghai 6th People's Hospital; Shanghai Changzheng Hospital; Shanghai Minhang Central Hospital; Shanghai Putuo District Center Hospital; Shanghai Yueyang Integrated Medicine Hospital; ShuGuang Hospital; The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine; Tongji Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Xinqiao Hospital of Chongqing; Zhujiang Hospital

Criteria

Inclusion Criteria:

1. Age 18-75 years;

2. Gender, nationality;

3. Pixushuifan syndrome, IMN confirmed by renal biopsy and clinical examination;

4. Treatment invalided by two or more than two kinds of Hormone or immunosuppressive agents ;

5. CKD phase 1-3（eGFR（EPI Formula）≥30ml/min/1.73m2）

Exclusion Criteria:

1. Progressive MN (progressive renal impairment, renal biopsy confirmed Necrotic Vasculitis and Large crescent formation>50%), combined with IgA nephropathy, diabetic nephropathy and other renal diseases;

2. Anti-nuclear antibodies, double stranded DNA, ANCA or other indicators of immune disorders;

3. Active hepatitis B and liver function test sustained abnormal;

4. Patients with malignant tumor or have a history of cancer, HIV infection, history of mental illness, acute central nervous system diseases, severe gastrointestinal diseases;

5. Merger with other serious disease and dysfunction of the organ;

6. Gravid or lactation woman;

7. Other clinical trials are being studied.